ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

CNS Drug Reviews

Volumn 10, Issue 2, 2004, Pages 167-182

  Rueter, Lynne E ^a   Anderson, David J ^a   Briggs, Clark A ^a   Donnelly Roberts, Diana L ^a   Gintant, Gary A ^a   Gopalakrishnan, Murali ^a   Lin, Nan Horng ^a   Osinski, Mark A ^a   Reinhart, Glenn A ^a   Buckley, Michael J ^a   Martin, Ruth L ^a   McDermott, Jeffrey S ^a   Preusser, Lee C ^a   Seifert, Terese R ^a   Su, Zhi ^a   Cox, Bryan F ^a   Decker, Michael W ^a   Sullivan, James P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 089; Alzheimer's disease; Attention deficit disorder; Cognitive disorders; Neuronal nicotinic acetylcholine receptor

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; ALPHA BUNGAROTOXIN; NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST; NICOTINIC AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ACTION POTENTIAL; AGING; ANIMAL BEHAVIOR; ATAXIA; BINDING AFFINITY; BINDING SITE; BRAIN SYNAPTOSOME; CARDIOVASCULAR SYMPTOM; CATION TRANSPORT; CELL PROTECTION; COGNITION; COGNITIVE DEFECT; DOPAMINE RELEASE; DOSE RESPONSE; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ELECTROPHYSIOLOGY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HIPPOCAMPUS; HUMAN; HYPOTHERMIA; IN VITRO STUDY; ION TRANSPORT; LIGAND BINDING; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; REVIEW; SEIZURE; TASK PERFORMANCE;

EID: 20244384658     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2004.tb00011.x     Document Type: Review

References (43)

1. Americ SP, Bannon AW, Brioni JD, et al. ABT-089: an orally effective cholinergic channel modulator (ChCM) with cognitive enhancement and neuroprotective action. In: Becker R and Giacobini E, Eds. Alzheimer Disease: From Molecular Biology to Therapy. Boston: Birkhäuser, 1996;287-291.
2. 125I] α-bungarotoxin autoradiography. Neuroscience 1998;83:1113-1122.
3. Beani L, Antonelli T, Tomasini MC, Marani L, Bianchi C. The nicotinic modulation of [H-3]D-aspartate outflow in primary cultures of rat neocortical neurons: Effect of acute and long term nicotine treatment. Neuropharmacology 2000;39:2646-2653.
4. Bertrand D., Devillers-Thiéry A, Revah F, et al. Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. Proc Natl Acad Sci USA 1992;89:1261-1265.
5. 7 nicotinic receptor. Proc Natl Acad Sci USA 1993;90:6971-6975.
6. 7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 1998;37:1095-1102.
7. 7 nicotinic acetylcholine receptor: Distinct pharmacology of the human α7V274T variant. Eur J Pharmacol 1999;366:301-308.
8. Buccafusco JJ, Jackson WJ. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging 1991;12:233-238.
9. Cordero-Erausquin M, Marubio LM, Klink R, Changeux J-P. Nicotinic receptor function: New perspectives from knockout mice. Trends Pharmacol Sci 2000;21:211-217.
10. Decker MW, Bannon AW, Curzon P, et al. ABT-089 [2-methyl-3-(2-(S)- pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther 1997;283:247-258.
11. Decker MW, Majchrzak MJ, Americ SP. Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol Biochem Behav 1993;45:571-576.
12. Donnelly-Roberts DL, Brioni JD. Preclinical evidence on the neuroprotective effects of nicotinic ligands. In: Arneric, SP, Brioni, JD, Eds. Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities. Indianapolis: Wiley-Liss, Inc., 1999:337-348.
13. Donnelly-Roberts DL, Xue IC, Americ SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res 1996;719: 36-44.
14. Ferris SH. Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2003;4:2305-2313.
15. Fu Y, Matta SG, Sharp BM. Local α-bungarotoxin-sensitive nicotinic receptors modulate hippocampal norepinephrine release by systemic nicotine. J Pharmacol Exp Ther 1999;289:133-139.
16. 2+ current through human neuronal alpha 7 nicotinic acetylcholine receptors. Cell Calcium 2003;34:205-209.
17. Girod R, Barazangi N, McGehee DS, Role LW. Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology 2000;39:2715-2725.
18. Haass M, Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 1997;10:657-65.
19. Kaiser S, Wonnacott S. alpha-Bungarotoxin-sensitive nicotinic receptors indirectly modulate [H-3]dopamine release in rat striatal slices via glutamate release. Mol Pharmacol 2000;58:312-318.
20. Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 1995;15:1231-1244.
21. Kofalvi A, Sperlagh B, Zelles T, Vizi ES. Long-lasting facilitation of 4-amino-n-[2,3-H-3]butyric acid ([H-3]GABA) release from rat hippocampal slices by nicotinic receptor activation. J Pharmacol Exp Ther 2000;295:453-462.
22. Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002;53:633-640.
23. Li X, Rainnie DG, McCarley RW, Greene RW. Presynaptic nicotinic receptors facilitate monoaminergic transmission. J Neurosci 1998;18:1904-1912.
24. Liang SD, Vizi ES. Positive feedback modulation of acetylcholine release from isolated rat superior cervical ganglion. J Pharmacol Exp Ther 1997;280:650-655.
25. Lin N-H, Gunn DE, Ryther KB, et al. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylinethoxy)pyridine (ABT-089): An orally bioavailable 3-pyridyl ether nicotine acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem 1997;40:385-390.
26. Lipton SA, Rosenberg, PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:934-940.
27. Lukas RJ. Characterization of curaremimetic neurotoxin binding sites on membrane fractions derived from the human neuroblastoma clonal line TE 671. J Neurochem 1986;45:1936-1941.
28. Lukas RJ. Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line. J Pharmacol Exp Ther 1993;265:294-302.
29. Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M. Direct evidence that release-stimulating alpha 7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 2002;80:1071-1078.
30. Marks MJ, Burch JB, Collins AC. Genetics of nicotine response in four inbred strains of mice. J Pharmacol Exp Ther 1983;226:291-302.
31. Marks MJ, Farnham DA, Grady SR, Collins AC. Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J Pharmacol Exp Ther 1993;264:542-552.
32. Newhouse PA, Kelton M. Nicotinic systems in central nervous systems disease: Degenerative disorders and beyond. Pharm Acta Helv 2000;74:91-101.
33. Papke RL, Porter Papke JK. Comparative pharmacology of rat and human alpha 7 nAChR conducted with net charge analysis. Br J Pharmacol 2002;137:49-61.
34. Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP, Buccafusco JJ. Central nicotinic receptor agonists ABT-418, ABT-089, and (-) nicotine reduce distractability in adult monkeys. Psychopharmacology 1998;136:50-58.
35. Roch J-M, Puttfarcken PS. Biological actions of the β-amyloid protein and its precursor. Curr Drugs 1996;1:9-16.
36. 7 expressed in Xenopus oocytes. Biophys J 1993;65:2614-2621.
37. 7: A nicotinic cation channel highly permeable to calcium. J Neurosci 1993;13: 596-604.
38. Skok VI. Nicotinic acetylcholine receptors in autonomic ganglia. Auton Neurosci 2002;18:1-11.
39. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorders in children. J Clin Psychiatry 2002;63(Suppl 12):16-22.
40. Sullivan JP, Donnelly-Roberts D, Briggs CA, et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 1997;283:235-246.
41. Tucci SA, Genn RF, File SE. Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: Possible role of alpha 7 receptors. Neuropharmacology 2003;44:367-373.
42. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(Suppl 12):50-55.
43. Yamada K, Toshitaka N. Therapeutic approaches to the treatment of Alzheimer's disease. Drugs Today 2002;38:631-637.